angiogenesis ͉ cell therapy ͉ hypoxia ͉ prolyl hydroxylation
S
tenosis of the vasculature that supplies the legs can lead to critical limb ischemia (1), a condition in which perfusion is insufficient to maintain tissue viability, leading to necrosis and ultimately amputation, despite advances in available medical treatment (2, 3) . Ischemia induces the production of angiogenic cytokines that elicit sprouting of new capillaries (angiogenesis) and remodeling of existing conduit vessels (arteriogenesis). In mouse models, limb ischemia induces the mobilization of a heterogeneous population of bone marrow-derived angiogenic cells (BMDACs), promoting recovery of perfusion and limb salvage (4) . It is thought that BMDACs exert their beneficial effect through the incorporation of endothelial progenitor cells into new or remodeling vessels (5) and/or the production of angiogenic cytokines by myeloid, mesenchymal, and hematopoietic stem cells (6, 7) . Recent work suggests that many prior studies used inadequate criteria to define endothelial progenitor cells and that most BMDACs are in fact proangiogenic myeloid cells (8) .
Hypoxia-inducible factor (HIF)-1 is a transcription factor that mediates adaptive responses to hypoxia/ischemia. HIF-1 is a heterodimer consisting of O 2 -regulated HIF-1␣ and constitutively expressed HIF-1␤ subunits (9) . HIF-2␣ is also O 2 -regulated, dimerizes with HIF-1␤, and has been implicated in vascular responses to ischemia (10, 11) . HIF-1 regulates the expression of genes encoding angiogenic cytokines, such as VEGF, placental growth factor (PLGF), stromal-derived factor (SDF)-1, and their cognate receptors VEGFR1, VEGFR2, and CXCR4 (12) (13) (14) . HIF-1 activity decreases with age and is linked to a poor angiogenic response in old animals, which reflects deficient production of angiogenic cytokines and impaired mobilization of BMDACs (4, 15, 16) . AdCA5, an adenovirus encoding a constitutively active form of HIF-1␣, enhances angiogenesis, arteriogenesis, and the number of circulating angiogenic cells in animal models (4, 12, 17) . Adeno-associated virus transduction of a stabilized form of HIF-1␣ was superior to VEGF in stimulating angiogenesis in skeletal muscle (18) . A phase I trial for no-option patients with critical limb ischemia showed no significant adverse effects after administration of adenovirus encoding a HIF-1␣/VP-16 fusion protein (19) .
Whereas AdCA5 delivery to muscle improves production of angiogenic cytokines, it does not address the functional impairment of BMDACs associated with aging (20, 21) . To promote vascular remodeling, BMDACs must be recruited to and retained in the ischemic tissue. Integrin expression in BMDACs may be critical for their interaction with endothelial cells and their proangiogenic effects (22) . Exposure of leukocytes to hypoxia increases their endothelial adhesion as a result of HIF-1-dependent induction of ␤ 2 integrins (23). On the basis of these findings, we hypothesized that induction of HIF-1 in BMDACs increases their retention in ischemic tissue. To induce HIF-1, we cultured BMDACs in dimethyloxalylglycine (DMOG), a prolyl-4-hydroxylase inhibitor, which blocks the O 2 -dependent degradation of HIF-1␣ and HIF-2␣ and has been shown to improve recovery in mouse models of intestinal and cerebral ischemia (24) (25) (26) .
Effect of AdCA5 Administration. Immediately after surgery, a total dose of 2 ϫ 10 8 plaque-forming units (pfu) of AdCA5 was injected into the adductor and gastrocnemius muscles of the ischemic limb. Saline and an adenovirus encoding Escherichia coli ␤-galactosidase (AdLacZ) were used as controls. AdCA5 increased maxLPR in young mice [0.69 Ϯ 0.02 (AdCA5) vs. 0.52 Ϯ 0.03 (saline); P Ͻ 0.05] but not in old mice [0.14 Ϯ 0.02 (AdCA5) vs. 0.12 Ϯ 0.02 (saline)] (Fig. 1B) . AdCA5 did not increase limb salvage in old mice when compared to saline controls (100% tissue necrosis in both groups; Fig. 1D , Right). were injected via tail vein 24 h after induction of limb ischemia. We did not observe significant differences in the recovery of perfusion, motor impairment, or limb salvage in young mice when we compared the saline control group against either vehicle-or DMOG-treated cells ( Fig. 1 B-D, Left) , showing that intravenous (IV) BMDAC administration did not induce a beneficial effect at this dose. In contrast, the combination of intramuscular (IM) AdCA5 and IV administration of DMOGtreated BMDACs significantly increased maxLPR in young mice compared to AdCA5-and saline-injected mice (0.80 Ϯ 0.02 vs. 0.69 Ϯ 0.02 and 0.52 Ϯ 0.03, respectively, P Ͻ 0.05; Fig. 1 A and  B) . In old mice, combined treatment increased maxLPR compared to the AdCA5-and saline-injected groups (0.27 Ϯ 0.02 vs. 0.14 Ϯ 0.02 and 0.12 Ϯ 0.02, respectively, P Ͻ 0.001; Fig treatment) vs. 2.7 Ϯ 0.2 (AdCA5) and 2.8 Ϯ 0.2 (saline), P Ͻ 0.05; Fig. 1C ]. Most importantly, there was a significant increase in limb salvage from 0% in the saline-and AdCA5-treated groups to 33% in the combined therapy group (P ϭ 0.035, 2 test; Fig. 1D ). Unexpectedly, the combination of IM AdLacZ and IV DMOG-treated cells in young mice reduced maxLPR, increased motor impairment, and reduced limb salvage ( Fig. 1 B-D) , indicating that AdLacZ was unsuitable as a control for combined therapy. Recent studies focused on the transduction of endothelial cells with adenoviral vectors have demonstrated nonspecific antiangiogenic and proinflammatory effects (27, 28) .
Molecular Characterization of DMOG-treated BMDACs.
Immunoblot analysis revealed a marked induction of both HIF-1␣ and HIF-2␣ protein after 4 h of exposure to DMOG ( Fig. 2A) . Reverse transcription (RT) and quantitative real-time PCR (qPCR), using specific primers (Table S1 ) revealed a 25-fold increase in GLUT1 and a 5.2-fold increase in VEGFR1 mRNA expression, whereas expression of VEGFR2, CXCR4, and CXCR7 mRNA was not increased in DMOG-treated BMDACs (Fig. 2B) . We hypothesized that DMOG may increase the sensitivity of BMDACs to angiogenic cytokines (such as VEGF, PLGF, and SDF-1) through HIF-1-mediated upregulation of their cognate receptors (i.e., VEGFR2, VEGFR1, and CXCR4), thereby increasing homing of BMDACs to the ischemic limb. Culture of bone marrow cells under endothelial growth conditions for 4 d selected for cells that expressed CD45, VEGFR1, and VEGFR2 (Fig. 2C ). Exposure to DMOG significantly increased the percentage of CD31 ϩ cells and also augmented the percentage and mean fluorescence intensity of VEGFR2 ϩ cells (Fig. 2C) . The percentage of BMDACs bearing progenitor cell markers such as Sca1 ϩ and c-kit ϩ was reduced by DMOG treatment (15 to 8% and 5 to 2%, respectively; P Ͻ 0.05). In contrast, DMOG increased the percentage of VEGFR1 ϩ / CD31 ϩ and VEGFR2 ϩ /CD31 ϩ cells (Fig. 2D ).
BMDAC Homing and Retention. IM AdCA5 injection was previously shown to induce VEGF and PLGF expression in ischemic muscle (4, 17) . Because VEGFR1/VEGFR2 surface expression was observed in the majority of BMDACs, we studied whether AdCA5 injection increased BMDAC homing after IV injection of vehicle-or DMOG-treated cells. BMDACs from male donors were injected into young female mice 24 h after femoral artery ligation. To analyze early homing of BMDACs to ischemic tissue (as opposed to subsequent retention), we isolated the ischemic and nonischemic gastrocnemius muscles 8 h after IV injection of BMDACs and performed qPCR using primers specific for Sry (Table S2) , a gene located on the Y chromosome. The assay had a log-linear range of four orders of magnitude and a lower detection limit of 2.7 copies (Fig. S1 ). The amount of Sry DNA in the gastrocnemius muscle of sham-operated mice was below the limit of detection, indicating little or no BMDAC homing to nonischemic tissue. Ischemia induced significant BMDAC homing in all conditions (pooled average ϭ 51 Ϯ 7 copies; Fig. 3 ). IM AdCA5 was sufficient to increase BMDAC homing to ischemic muscle, because it recruited both vehicle-and DMOG-treated BMDACs (pooled average ϭ 208 Ϯ 29 copies; Fig. 3 ). This level of BMDAC homing was significantly higher in comparison to all experimental groups that did not involve AdCA5 administration. These results confirmed our expectation that by augmenting the production of angiogenic cytokines, AdCA5 increases homing of BMDACs. However, contrary to our expectations, DMOG treatment of BMDACs did not increase their homing to ischemic tissue 8 h after IV cell injection. To explain the beneficial effect of DMOG-treated BMDACs when combined with IM AdCA5, we hypothesized that following homing, DMOG treatment may promote the retention of BMDACs in ischemic tissue. Functional ␤ 2 integrins are heterodimers of CD11 and CD18 subunits and play an important role in the retention of angiogenic cells in ischemic tissues (22) . Compared to vehicle, DMOG treatment of BMDACs increased the expression of mRNAs encoding CD11a (6.3-fold), CD11b (2.8-fold), CD11c (3.4-fold), and CD18 (9.5-fold) (Fig. 4A) . DMOG increased the percentage of BMDACs that were CD11a 4B). Both LFA-1 and Mac-1 are known to be involved in the attachment of leukocytes to endothelium and are present at higher numbers on the surface of hypoxic neutrophils (29, 30) . To test BMDAC binding to endothelium we used a dynamic microfluidic adhesion assay, in which BMDACs were perfused under conditions of physiological shear stress (0.1 Pa) through channels lined with human umbilical vein endothelial cells (HUVECs) preexposed to hypoxia to simulate the ischemic tissue microenvironment (Fig. 5A and Movie S1). The number of perfused DMOG-treated BMDACs that adhered to vascular endothelial cells was 2.5-to Ϯ0.6-fold higher than the number of adherent vehicle-treated BMDACs ( Fig. 5B ; P Ͻ 0.001). DMOG treatment enhanced BMDAC adhesion when assayed with HUVECs cultured at either 20 or 1% O 2 . Increasing the perfusion pressure from 0.1 to 2.5 Pa was sufficient to remove BMDACs bound to HUVECs cultured at 20% O 2 but not at 1% O 2 , which is consistent with the known activation of vascular endothelium in ischemic tissue. To determine whether the effect of DMOG was HIF-1-dependent, BMDACs were cultured in the presence of DMOG and digoxin, which inhibits HIF-1␣ and HIF-2␣ protein synthesis (31) . Digoxin blocked the effect of DMOG on BMDAC adhesion to hypoxic endothelium (Fig. 5B) .
DMOG may inhibit many hydroxylases in BMDACs in addition to those that regulate HIF-1␣ and HIF-2␣. To determine whether expression of a constitutively active form of HIF-1␣ was sufficient to increase the adhesion of BMDACs to endothelial cells ex vivo, BMDACs were transduced with the lentiviral vector LvCA5. Compared to BMDACs transduced with LvEGFP, a control lentiviral vector, LvCA5 increased adhesion of BMDACs to nonhypoxic and hypoxic HUVECs in the microfluidics assay by 1.9-fold and 4.0-fold, respectively (P Ͻ 0.01; Fig. 5C ). Thus, HIF-1␣ is necessary and sufficient to mediate increased adherence of BMDACs to vascular endothelial cells under physiologically relevant perfusion pressures.
Because exposure of HUVECs to 1% O 2 strengthened BMDAC adhesion, we studied the expression of the endothelial cell surface proteins ICAM-1 and E-selectin, which mediate adhesion by interacting with ␤ 2 integrins. Flow cytometric analysis of HUVECs showed that Ͼ95% were ICAM-1 ϩ and Ͼ50% were E-selectin ϩ . Exposure of HUVECs to 1% O 2 for 24 h increased the mean fluorescence intensity of ICAM-1 ϩ and E-selectin ϩ cells by 1.6-and 1.4-fold, respectively (Fig. 5D) . These results provide a molecular mechanism for the increased stability of interaction between BMDACs and hypoxic HUVECs.
To determine whether ␤ 2 integrins were required for endothelial adhesion, BMDACs were incubated with an anti-CD18 antibody. DMOG-treated BMDACs incubated with an isotypematched control antibody showed a 3.1-fold increase in attachment to HUVECs, whereas incubation with a neutralizing antibody against CD18 reduced the number of adherent cells in the microfluidics assay to levels that were not significantly different from vehicle-treated BMDACs incubated with isotypematched control antibody (Fig. 5E ). These results demonstrate that the increased adhesion of DMOG-treated BMDACs to endothelial cells is dependent upon ␤ 2 integrin function.
Discussion
This study demonstrates that a therapeutic strategy based on combined HIF-1␣ gene therapy and BMDAC therapy is capable of improving perfusion, reducing motor impairment, and increasing limb salvage in a mouse model of critical limb ischemia. Remarkably, combined treatment induced significant recovery in old mice, whereas gene therapy alone was not sufficient at a dose associated with a significant response in young and middleaged mice (4) . Characterization of BMDAC surface receptors indicated that these cells were similar to bone marrow myeloid cells, although BMDACs express high levels of both VEGFR1 
, and CD11c ϩ /CD18 ϩ (CR4 ϩ ) BMDACs (n ϭ 3). Antibodies are listed in Table S3 . and VEGFR2. DMOG treatment of BMDACs increased HIF-1␣ and HIF-2␣ protein levels and transcriptional activity, as reflected in increased mRNAs encoded by the known HIF-1 target genes GLUT1 and VEGFR1. DMOG also increased cell surface levels of CD31 (PECAM-1), which is a marker for endothelial and proangiogenic myeloid cells (7) . We previously showed that IM AdCA5 induced mobilization of BMDACs into peripheral blood (4) and results of the present study demonstrate that AdCA5 also significantly increased BMDAC homing to ischemic muscle. Complementing the effect of IM AdCA5 on homing, our results demonstrate that ␤ 2 integrin expression is increased at both the mRNA and protein levels in DMOGtreated BMDACs. Using a custom-designed microfluidics device, we found that DMOG increased the adhesion of BMDACs to HUVECs under physiologically relevant perfusion pressures. Exposure of HUVECs to 1% O 2 increased the expression of ICAM-1 and E-selectin, the ␤ 2 integrin ligands known to participate in adhesion of leukocytes to endothelium. The attachment of BMDACs to hypoxic HUVECs was very strong, because it was not possible to detach the BMDACs at a perfusion pressure of 2.5 Pa, which is comparable to arterial levels of wall shear stress (32) . HIF-1␣ expression was necessary and sufficient to increase BMDAC adhesion to endothelial cells. Finally, CD18 (␤ 2 integrin) functional blockade abolished the augmented endothelial adhesion of DMOG-treated BMDACs.
While this work was in progress, several attempts to improve the efficacy of so-called ''endothelial progenitor cell'' therapy through expression of HIF-1␣, using vectors that were transduced by either electroporation (33) or adenoviral transduction (34), were reported. Although promising, these reports used the wild-type HIF-1␣ sequence, thus relying on continuous hypoxic culture to avoid degradation of HIF-1. In addition, myeloid cells are notoriously resistant to transduction by electroporation or adenoviral infection. Finally, large numbers of cells (5 ϫ 10 6 ) were injected into ischemic recipients. To overcome these technical limitations, we treated BMDACs with DMOG ex vivo to induce HIF-1␣ and HIF-2␣ without exposure of cells to a recombinant vector and to avoid the potential blunting of homing signals from the ischemic limb that might occur with systemic DMOG treatment. Because dose scaling is an important problem in terms of translation to clinical studies, we used the lowest AdCA5 dose with positive angiogenic effects as described in previous studies (4, 12, 17) . We also injected a smaller number of BMDACs (5 ϫ 10 5 cells). Despite the lack of effect of DMOG-treated cells alone, the combination of IV DMOGtreated BMDACs and IM AdCA5 induced functional recovery and limb salvage in old mice, in which angiogenic responses are impaired as compared to young mice (4, 16), thus more closely resembling patients with critical limb ischemia. Finally, in addition to the synergistic therapeutic effects of IM AdCA5 and IV DMOG-treated BMDACs, stable retention of BMDACs in ischemic tissue is further aided by hypoxia-induced expression in vascular endothelial cells of ICAM-1 and E-selectin, which are known to interact with ␤ 2 integrins, and were recently shown to be involved in BMDAC homing to ischemic myocardium (35) and muscle (36, 37) .
The results of this study demonstrate that combined AdCA5 gene therapy and DMOG-treated BMDAC therapy act synergistically to increase the recovery of blood flow following femoral artery ligation, thereby preventing tissue necrosis. At the molecular level, this synergistic effect is due at least in part to the fact that AdCA5 enhances the initial homing of BMDACs, whereas DMOG treatment increases the retention of recruited cells in the ischemic tissue. The improved efficacy of this treatment strategy addresses issues of feasibility, in terms of the required doses of adenovirus and BMDACs, and the ability to BMDACs were preincubated with a blocking CD18 (␣CD18) antibody or isotype control and analyzed for endothelial adhesion.
